FDA should consider drug-therapy regimens | Science
In his In Depth story “What’s next for psychedelics after MDMA rejection?” (16 August, p. 7src2), K. Kupferschmidt describes how the US Food & Drug Administration (FDA) turned down the application of a combination of 3,4-methylenedioxymethamphetamine (MDMA), also known as ecstasy, and psychotherapy for posttraumatic stress disorder…
In his In Depth story “What’s next for psychedelics after MDMA rejection?” (16 August, p. 7src2), K. Kupferschmidt describes how the US Food & Drug Administration (FDA) turned down the application of a combination of 3,4-methylenedioxymethamphetamine (MDMA), also known as ecstasy, and psychotherapy for posttraumatic stress disorder…
Read More
About Author
